Relman A S
Clin Pharmacol Ther. 1979 May;25(5 Pt 2):673-6. doi: 10.1002/cpt1979255part2673.
If cooperative clinical trials are to compete with other types of clinical research for the attention of physician investigators, they must offer rewards in the form of publication credits and academic recognition. Large-scale multi-institutional clinical trials provide less opportunity for authorship than individual or small-group research. This problem cannot be solved by attempts to multiply publications unnecessarily or to blur the meaning of authorship. Only those who contribute significantly to the design and interpretation of an experiment should be designated as authors; journals should be prepared to recognize all those who meet that test. Increased opportunities for authorship can be provided if the National Institutes of Health (NIH) encourage small-scale clinical trials carried out by individual investigators. Academic recognition of the clinical investigator in increasing and would be greatly strengthened by an NIH policy of greater support for this kind of research.
如果合作性临床试验要与其他类型的临床研究竞争,以吸引医师研究者的关注,它们就必须以发表文章的署名权和学术认可的形式提供奖励。大规模多机构临床试验提供的署名机会比个人或小组研究少。试图不必要地增加出版物数量或模糊作者身份的含义并不能解决这个问题。只有那些对实验设计和解释做出重大贡献的人才能被指定为作者;期刊应该准备好认可所有符合这一标准的人。如果美国国立卫生研究院(NIH)鼓励个体研究者开展小规模临床试验,就可以提供更多的署名机会。临床研究者的学术认可度在不断提高,NIH对这类研究给予更多支持的政策将极大地加强这种认可度。